This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi and Novartis settle patent litigation over gene-0therapy drug

( November 15, 2024, 00:28 GMT | Official Statement) -- MLex Summary: A US patent litigation between Sanofi's subsidiary Genzyme and Novartis Gene Therapies, Novartis Pharmaceutical, and Novartis AG has beem settled. Biopharmaceutical company MediciNova, which is entitled to receive damages through the settlement, released the news in a statement dated Nov. 11. The infringement complaint over US Patent No. 9,051,542 over the recombinant adeno-associated virus vectors for the gene therapy drug Zolgensmabetween was filed in  the U.S. District Court for the District of Delaware on Feb. 23, 2022. Statement follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections